1. OC-0067 De-escalation of radiation therapy after primary chemotherapy in cT1-2N1 breast cancer (RAPCHEM). (August 2021) Authors: de Wild, S.; de Munck, L.; Verloop, J.; van Dalen, T.; Elkhuizen, P.; Houben, R.; van Leeuwen, E.; Linn, S.; Pijnappel, R.; Poortmans, P.; Strobbe, L.; Wesseling, J.; Voogd, A.; Boersma, L. Journal: Radiotherapy and oncology Issue: Volume 161(2021)supplement Page Start: S41 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. OC-0592 5 year results of the Preoperative Accelerated Partial Breast Irradiation (PAPBI) trial. (April 2019) Authors: Bosma, S.; Leij van der, F.; Vreeswijk, S.; Vijver van der, M.; Rivera, S.; Foukakis, T.; Bongard van den, D.; Rutgers, E.; Scholten, A.; Bartelink, H.; Elkhuizen, P. Journal: Radiotherapy and oncology Issue: Volume 133(2019)Supplement 1 Page Start: S310 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. PO-0759 Radiotherapy After Primary CHEMotherapy (RAPCHEM): protocol adherence in a Dutch registration study. (April 2019) Authors: Boersma, L.; Elkhuizen, P.; Houben, R.; Van Leeuwen, E.; Linn, S.; De Munck, L.; Pijnappel, R.; Strobbe, L.; Van Dalen, T.; Verloop, J.; Voogd, A.; Wessling, J.; Poortmans, P. Journal: Radiotherapy and oncology Issue: Volume 133(2019)Supplement 1 Page Start: S389 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. PO-0987: Target volume changes of brain metastases during fractionated SRS. (April 2018) Authors: Hessen, E.; Damen, P.; Jasperse, B.; Dewit, L.; Elkhuizen, P.; Van Mourik, A.; Wittkamper, F.; Damen, E.; Van der Heide, U.; Hanssens, P.; Schasfoort, J.; Nijkamp, J.; Borst, G. Journal: Radiotherapy and oncology Issue: Volume 127(2018)Supplement 1 Page Start: S548 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. Risk of subsequent in situ and invasive lesions after a primary diagnosis of ductal carcinoma in situ with follow-up time up to 28 years. (October 2020) Authors: Van Seijen, M.; Lips, E.H.; Fu, L.P.; Groen, E.; van Duijnhoven, F.; Thompson, A.; Elkhuizen, P.; Schmidt, M.K.; Wesseling, J.; Schaapveld, M. Journal: European journal of cancer Issue: Volume 138(2020)Supplement 1 Page Start: S10 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. Tailored axillary treatment after neoadjuvant systemic therapy in clinically node-positive breast cancer patients is safe: 3-year follow-up of the MARI protocol. (October 2020) Authors: Van Loevezijn, A.; van der Noordaa, M.E.M.; van Duijnhoven, F.; Groen, E.J.; Stokkel, M.P.M.; Loo, C.E.; Elkhuizen, P.; Russell, N.S.; Vrancken-Peeters, M.J. Journal: European journal of cancer Issue: Volume 138(2020)Supplement 1 Page Start: S3 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗